Results 101 to 110 of about 9,343 (245)

Efficacy and safety of burosumab compared with conventional therapy in patients with X-linked hypophosphatemia: A systematic review

Archives of Endocrinology and Metabolism
Burosumab, a monoclonal antibody directed against the fibroblast growth factor 23 (FGF23), has been approved for the treatment of X-linked hypophosphatemia (XLH).
Manjunath Havalappa Dodamani, Samantha Cheryl Kumar, Samiksha Bhattacharjee, Rohit Barnabas, Sandeep Kumar, Anurag Ranjan Lila, Saba Samad Memon, Manjiri Karlekar, Virendra A. Patil, Tushar R. Bandgar   +9 more
doaj   +1 more source

Biomechanical Impact of Phosphate Wasting on Articular Cartilage Using the Murine Hyp Model of X‐linked hypophosphatemia [PDF]

, 2023
Carolyn M. Macica, Steven M. Tommasini
openalex   +1 more source

Npp1 promotes atherosclerosis in ApoE knockout mice. [PDF]

, 2011
Ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) generates inorganic pyrophosphate (PP(i)), a physiologic inhibitor of hydroxyapatite deposition.
Nitschke, Yvonne, Rutsch, Frank, Terkeltaub, Robert, Weissen-Plenz, Gabriele   +3 more
core   +1 more source

Association Between Arterial Stiffness and Bone Microarchitectural Deterioration in Type 2 Diabetes: A Cross‐Sectional Study

Journal of Diabetes, Volume 17, Issue 12, December 2025.
Identified baPWV as a novel independent influencing factor of bone microarchitecture deterioration in T2DM, elucidating a bone–vascular axis. Proposes baPWV as a practical indicator for simultaneous cardiovascular and fracture risk assessment in diabetic patients.
Yangting Wang, Xiaoting Chen, Jinjian Xu, Qifeng Ying, Lizhi Liang, Xiaohong Wu   +5 more
wiley   +1 more source

Correction to: Phenotypic characterization of X-linked hypophosphatemia in pediatric Spanish population

Orphanet Journal of Rare Diseases, 2021
An amendment to this paper has been published and can be accessed via the original article.
Enrique Rodríguez-Rubio, Helena Gil-Peña, Sara Chocron, Leire Madariaga, Francisco de la Cerda-Ojeda, Marta Fernández-Fernández, Carmen de Lucas-Collantes, Marta Gil, María Isabel Luis-Yanes, Inés Vergara, Juan David González-Rodríguez, Susana Ferrando, Montserrat Antón-Gamero, Marta Carrasco Hidalgo-Barquero, Angustias Fernández-Escribano, Mº Ángeles Fernández-Maseda, Laura Espinosa, Aniana Oliet, Antonio Vicente, Gema Ariceta, Fernando Santos, RenalTubeGroup   +21 more
doaj   +1 more source

A secretory kinase complex regulates extracellular protein phosphorylation. [PDF]

, 2015
Although numerous extracellular phosphoproteins have been identified, the protein kinases within the secretory pathway have only recently been discovered, and their regulation is virtually unexplored.
Cui, Jixin, Dixon, Jack E, Rahdar, Meghdad, Tagliabracci, Vincent S, Wen, Jianzhong, Xiao, Junyu   +5 more
core   +2 more sources

X-linked familial hypophosphatemia

Arab Journal of Rheumatology
Abstract: Osteomalacia is a diffuse bone disorder characterized by increased bone fragility, and it represents in adults the equivalent of rickets seen in children, sharing the same causes. This condition mainly results from Vitamin D deficiency, but in some cases, it may be due to renal phosphate wasting, which can be hereditary, acquired ...
Boutaina Zerouali, Kawtar Nassar, Soukaina Zaher, Ahlam Ajerouassi, Wafae Rachidi, Saadia Janani   +5 more
openaire   +1 more source

Urinary Calcium and Phosphorus Excretion in Vitamin D‐Sufficient Preterm Infants: Establishing Age‐Specific Normative Data

Acta Paediatrica, Volume 114, Issue 12, Page 3267-3278, December 2025.
ABSTRACT Aim This study evaluated urinary calcium (Ca) and phosphorus (P) excretion in very low birth weight infants ( < 1500 g, VLBW) without severe morbidity, treated with methylxanthines. Methods Eighty‐one VLBW infants were analysed. Urinary Ca and P and their creatinine ratios were measured biweekly until day 56.
Tomas Matejek, Veronika Pokorna, Vojtech Drahy, Lenka Zaloudkova, Vladimir Palicka, Sylva Skalova   +5 more
wiley   +1 more source

Surgical Treatment for Osteomalacia Induced by Causative Tumor in the Knee Joint Region: A Single‐Center Retrospective Clinical Study Over 10 Years

Orthopaedic Surgery, Volume 17, Issue 12, Page 3440-3455, December 2025.
The causative tumor for TIO in the knee joint region is hidden and has diverse locations, resulting in great challenges to endocrinologist and orthopedists. Due to the unique anatomical location and complex structure of the knee joint, orthopedic surgeons can adopt different surgical approaches to completely remove the causative tumor.
Shuzhong Liu, Xi Zhou, Jinyi Xing, Zhen Huo, Mingjing Zhang, Bo Yang, Yong Liu, Weibo Xia   +7 more
wiley   +1 more source

Impact of stopping burosumab treatment at the end of skeletal growth in adolescents with X-linked hypophosphatemia (XLH)

Bone Reports
Many adolescents with X-linked hypophosphatemia (XLH) currently have to stop treatment with burosumab at the end of skeletal growth. We describe the experience of a cohort of adolescents with XLH before, during, and after stopping burosumab (median ...
Charlotte Jarvis, Renuka Ramakrishnan, Poonam Dharmaraj, Talat Mushtaq, Sanjay Gupta, Angela Williams, Angela J. Rylands, Helen Barham, Annabel Nixon, Suma Uday   +9 more
doaj   +1 more source